JNJ

188.2

+1.42%↑

ABT

124.93

-0.02%↓

TMO

562.47

-0.2%↓

ISRG

532.62

-1.31%↓

DHR

216.05

-0.29%↓

JNJ

188.2

+1.42%↑

ABT

124.93

-0.02%↓

TMO

562.47

-0.2%↓

ISRG

532.62

-1.31%↓

DHR

216.05

-0.29%↓

JNJ

188.2

+1.42%↑

ABT

124.93

-0.02%↓

TMO

562.47

-0.2%↓

ISRG

532.62

-1.31%↓

DHR

216.05

-0.29%↓

JNJ

188.2

+1.42%↑

ABT

124.93

-0.02%↓

TMO

562.47

-0.2%↓

ISRG

532.62

-1.31%↓

DHR

216.05

-0.29%↓

JNJ

188.2

+1.42%↑

ABT

124.93

-0.02%↓

TMO

562.47

-0.2%↓

ISRG

532.62

-1.31%↓

DHR

216.05

-0.29%↓

Search

Erasca Inc

Open

2.51 5.46

Overview

Share price change

24h

Current

Min

2.33

Max

2.4699999999999998

Key metrics

By Trading Economics

Income

-2.9M

-34M

Profit margin

-768.16

Employees

103

EBITDA

-2.5M

-38M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+39.34% upside

Dividends

By Dow Jones

Next Earnings

10 Nov 2025

Market Stats

By TradingEconomics

Market Cap

259M

678M

Previous open

-2.95

Previous close

2.51

Technical Score

By Trading Central

Confidence

Bearish Evidence

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Oct 2025, 23:28 UTC

Hot Stocks

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 Oct 2025, 23:07 UTC

Earnings

Prudential PLC 3Q New Business Profit Up 13%

30 Oct 2025, 00:00 UTC

Earnings

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 Oct 2025, 00:00 UTC

Earnings

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 Oct 2025, 00:00 UTC

Earnings

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 Oct 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 Oct 2025, 23:40 UTC

Earnings

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 Oct 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 Oct 2025, 23:25 UTC

Earnings

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 Oct 2025, 22:51 UTC

Earnings

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 Oct 2025, 22:45 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 Oct 2025, 22:41 UTC

Earnings

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 Oct 2025, 22:41 UTC

Earnings

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 Oct 2025, 22:09 UTC

Earnings

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 Oct 2025, 22:08 UTC

Market Talk
Earnings

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 Oct 2025, 21:58 UTC

Earnings

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 Oct 2025, 21:58 UTC

Earnings

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 Oct 2025, 21:57 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 Oct 2025, 21:54 UTC

Earnings

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 Oct 2025, 21:46 UTC

Earnings

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 Oct 2025, 21:43 UTC

Earnings

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 Oct 2025, 21:43 UTC

Earnings

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 Oct 2025, 21:42 UTC

Earnings

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 Oct 2025, 21:42 UTC

Earnings

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 Oct 2025, 21:41 UTC

Earnings

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 Oct 2025, 21:41 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 Oct 2025, 21:41 UTC

Earnings

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 Oct 2025, 21:41 UTC

Earnings

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 Oct 2025, 21:40 UTC

Earnings

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 Oct 2025, 21:39 UTC

Earnings

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

39.34% upside

12 Months Forecast

Average 3.4 USD  39.34%

High 6 USD

Low 1 USD

Based on 5 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

1.39 / 1.44Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Very Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat